Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.38 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.35 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.35 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | LIPE | Q05469 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.30 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12936374 | 0.81 | FFAR1 (0.46) | LMNAFFAR1TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL10434333 | 0.81 | GAA (0.40) | LMNACYP2D6CYP2C19MAPK1GAA | |
| SCHEMBL18878377 | 0.75 | FFAR1 (0.40) | LMNAFFAR1CYP2C19POLBALDH1A1 | |
| SCHEMBL18878386 | 0.71 | POLB (0.36) | FFAR1POLBALDH1A1GAAL3MBTL1 | |
| SCHEMBL27985411 | 0.71 | ALDH1A1 (0.40) | LMNAPOLBALDH1A1SMN1; SMN2GAA | |
| SCHEMBL18878381 | 0.69 | KDM4E (0.40) | FFAR1TAS1R3TAS1R1POLBALDH1A1 | |
| SCHEMBL18878384 | 0.69 | FFAR1 (0.42) | LMNAFFAR1ALDH1A1GABRA1GABRB2 | |
| SCHEMBL4385920 | 0.68 | FFAR1 (0.50) | LMNAFFAR1CYP2D6CYP2C19ALDH1A1 | |
| SCHEMBL12936389 | 0.68 | FFAR1 (0.50) | LMNAFFAR1MAPK1GAA | |
| SCHEMBL14989194 | 0.67 | PTGS1 (0.47) | LMNAGAAGABRA1GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9951074-B2 | Dihydropteridinone derivatives and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-20170145013-A1 | DIHYDROPTERIDINONE DERIVATIVES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170145013-A1 | DIHYDROPTERIDINONE DERIVATIVES AND USES THEREOF | BRDT, BRD4, BRD3 | LMNA 753/4885FFAR1 4194/4885TAS1R3 4738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.